• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    This invention relates to heterocyclic compounds and, in particular, to the preparation of pristinamycin derivatives of the formula I, wherein the Y-H or dimethylamino group R - 3- or 4-quinuclidinyl, in the form of a single isomer or a mixture of isomers or their acid addition salts, which have an antibacterial effect. The purpose of the invention is to develop a method for producing compounds having the indicated action. The preparation is carried out by reacting the corresponding pristinamycin derivative with a thiol of the formula R-SH in an organic solvent medium, followed by isolating the title compound as a base or an acid addition salt. 3 tab. @ (I)
    公开号:SU1616520A3
    申请号:SU874202596
    申请日:1987-05-21
    公开日:1990-12-23
    发明作者:Баррьер Жан-Клод；Котрель Клод；Парис Жан-Марк
    申请人:Рон-Пуленк Санте (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new derivatives of pristin-amycin of the general formula
    CH,
    0
    HN
    with-
     Th%
    o-Vo-vsv-J o
    tr
    II
    ABOUT
    where Y is hydrogen or dimethylamino;
    R - 3- or 4-quinuclidinyl in the form of a single isomer or a mixture of isomers, or their acid addition salts,
    which have antibacterial action, in particular on staphylococcus aureus smith, and can be used in medicine.
    The purpose of the invention is to obtain new derivatives of pristinamycin, possess CM
    lower toxicity due to the exclusion of a clastogenic side effect.
    In the description, all the protons in the spectra are indicated by numbering, given in the following formula:
     tCHi, 3B CHj

    OL, X SNZ-5-H
    P
    Sd
    5P
    0
    N
    VH
    Er
     VHij
    Spectra were taken at 250 MHz in deuterochloroform; chemical displacements are expressed in ppm relative to the signal of tetramethylsilane. The following abbreviations are used: s - singlet; d- doublet; t is a triplet; mt is null, tiplet; ha - tight; dd - doublet of doublet; dt - doublet of triplet; ddd - doublet of doublet of doublet; dddd - doublet doublet doublet doublet.
    Example 1. To a solution of 4.4 g of 5 < RTI ID = 0.0 > -methylene prystanamicin 1d in a mixture of 40 cm of methanol and 20 cm of chloroform was added 2.8 g of 3-mercaptoquinuclidine, then the resulting solution was stirred for 44 hours at 20 ° C. The reaction mixture is concentrated to dryness under reduced pressure (2.7 kPa) at 30 ° C. The resulting residue is suspended in 100 cm of ethyl ether, then purified by flash chromatography at an average pressure of 50 kPa, using 40–53 mm silica (flash chromatography).
    Use the solvent - methylene chloride-methanol (90-10 vol.%), Selecting the fraction according to SHO, see. Fractions 11 to 35 are combined, then concentrated to dryness under reduced pressure (2.7 kPa) at. The residue is stirred at 120 cm of ethyl ether. The obtained solid is separated by filtration, then the filter is purified by flash chromatography (solvent — methylene chloride-methanol 85–15% by volume), selected from 100 cm each. Fractions 2 through 7 are concentrated, then concentrated to dryness.

    0
    five
    20
    25
    thirty
    35
    40
    45
    50
    under reduced pressure (2.7 kPa) at 30 ° C. The residue is stirred in 50 cm of ethyl ether, and the solid thus obtained is separated by filtration, washed 3 times with 5 cm of ethyl ether, then dried under reduced pressure (27 Pa) at 20 ° C. Thus, 1.7 g of (3-quinuclidinyl) -5o-thiomethyl-prig, tanamycin 1d are obtained in the form of a pale yellow solid with mp. 200 C.
    Nuclear Magnetic Resonance Spectrum (mixture of 4 isomers): 2.88 and 2.89 (2s, 4 - Ы (СНз) 2); 3.21 and 3.22 (2s, 4 - CH); 6.51 and 6.53 (2d, 2 i -NH-), 6.57 and 6.58 (2d, 4B); 7.82 and 7.85 (mt, 2 major isomers); 7.95 (mt, 1 and 2 of the minority isomers); 8.78 and 8.81 (2d, 6-NH- 2 related to the majority; voisomers); 8.98 and 9.0 (2d, 6-NH-2 refer to minority isomers).
    A 5% aqueous solution of (3-quinuclidinyl) -5-thiomethylprystin-amyc is obtained in 1d as hydrochloride: product 100 mg, 0.1N hydrochloric acid per 0.98 cm, distilled water is a sufficient amount for 2 ml.
    3-Mercapto-quinuclidine was prepared as follows.
    To a solution of 14.5 g of 3-acetylthioquinidium in 150 cm of methanol is added 0.5 g of sodium methoxide. The reaction mixture is then heated under reflux for 1 hour. 0.5 g of sodium methoxide is added, then it is heated under reflux for 2 hours. The reaction mixture is concentrated; dry under reduced pressure (2.7 kPa) at 40 ° C. To the residue obtained, add 40 cm of distilled water, then about 1 cm of acetic acid, in order to obtain a pH of about 8. The resulting mixture is extracted 3 times with 20 cm of methylene chloride. The combined organic phases are dried over sodium sulfate, filtered, then concentrated to dryness under uniform pressure (2.7 kPa) and temperature. The brown oil obtained is subjected to distillation under reduced pressure (920 Pa). The fraction distilled off at about 94 ° C is taken. Thus, 2.8 g of 3-mercapto-quinuclidine is obtained.
    five
    3-Lethylthio-quinuclidine was prepared as follows.
    To a solution containing 42 g of triphenylphosphine in 300 cm of tetrahydrofuran at 5 ° C under nitrogen atmosphere is added dropwise in 30 minutes to 31.6 cm of diisopropyl azodicarboxylate. The resulting suspension is then stirred for 30 minutes at. The suspension maintained at 5 ° C is added, for 30 minutes a solution of 10.2 g of 3-ox-quinuclidine and 11.4 cm of thioacetic acid in 600 cm of tetrahydrofuran. The reaction mixture is stirred for 20 hours at 20 ° C, then concentrated to dryness under reduced pressure (2.7 kPa) at 40 ° C. The resulting oil is dissolved in 400 cm of ethyl ether, then washed 3 times with 160 cm of hydrochloric acid. The combined aqueous phases are washed with 100 cm of ethyl ether and neutralized to a pH of about 7 by the addition of sodium bicarbonate. The pH of the resulting solution is adjusted to about 9 by adding a few drops of an aqueous solution of Yun sodium hydroxide. Extracted 3 times in 20) cm methylene chloride. The combined organic phases are dried on sodium sulfate, filtered and concentrated to dryness under reduced pressure: - pressure (2.7 kPa) at 30 ° C. Thus, 14.7 g of 3-acetylthioquinuclidine are obtained in the form of a brown oil (R 0.33; the solvent is methylene chloride-methanol 90-10 vol.%) Example 2. Similar to the method described in example 1, but starting from 6 , 15 g of 50-methylene-pristinamis-L 3-mercapto-quinucpidine (S) and, after two cleansings, by instant chromatography, selecting fractions of 50 cm each (first chromatography: solution-methylene chloride-methanol 90-10% by volume) , after concentration to dryness of fractions 12-36; (second instant chromatography: solvent: methylene chloride-methanol 9-10 vol.%), after concentration of fractions 3 to 20, 2.6 g of 3-quinuclidinyl (8) -5-thiomethylpristinamine 1d are obtained in the form of a pale powder.
    This product is obtained in the crystalline state as follows.
    2.6 g of 3-quinucpidinyl (5) -5U-thio-metigig-pristinamycin 1d is dissolved in 2Q cm of methanol. Get yellow
    65206
    solution. A crystalline precipitate appears after seeding for friction after filtration and drying at a low pressure (27 Pa) at. 1.2 g of 3-quinuclidinyl (S) -5o-thiomethyl-pristine "cina 1d are obtained in the form of white crystals with m.p. (crystallized product in combination with .Q methanol).
    Nuclear magnetic resonance spectrum; 1 isomer (traces of isomer at carbon level 5S); 0.62 (dd, i 16 and 6, 1H, sp); 1.6-2.30 (mt,
    NG - and 2.4 (d, I N1
     15, 1H, 5/3,): 2.5-2.75 (mt,
    1. Hjc5) and 1H -); 2.9-3.20 N
    (mt, -S - SNS, 1H, -CH,
    -.
    25 3.30 (mt, 1H, .4.98 (dd, I "14 and 7.5, 1H, 56,); 5.30 (mt, 2H, and%); 7.90 (dd, 1H, 1 ny).
    Z-Hinuclidinyl (5) -5 -thiomethyl - pristinamycin 1d can also be re-crystallized as follows. 17.4 g of 3-quinuclidinyl (5) -5 -thiomethyl | -prmstinamycin 1, is dissolved in 87 cm of acetone, pre, p, before boiling. The resulting 35 solution is filtered, then the insoluble part is rinsed with 10 cm of acetone. The crystals obtained after 3 hours are filtered, then dried. Recrystallization of the obtained 14.8 g of 0 from 75 cm of acetone under the same conditions gives after filtration, then drying. Under reduced pressure (90 Pa) at 12.2 g of white crystals with m.p. 185-190 C.
    5 3-Mercapto-quinuclidine (S) was prepared as follows.
    To a solution of 29 g of 3-acetylthio-quinuclidine (S) in 30 cm of methanol, kept approximately at, 30 cm of an aqueous solution of 10N sodium hydroxide is slowly added. The reaction mixture was stirred at 20 ° C for 2 hours. Then the pH of pe- was adjusted.
    Promotional mixture up to 9 by adding about 10 cm of acetic acid. The resulting mixture is extracted 3 times with 100 cm of methylene chloride. The organic phase is dried on sulphate.
    1616520
    sodium, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 30 ° C. The resulting residue is purified by distillation under reduced pressure (970 Pa). Thus, 12 g of 3-mercapto-quinuclidine (S) are obtained in the form of white crystals with m.p. , and distilled at 95 C at 970 Pa (-118 ° C, C 1.1, methanol).
    3-Acetylthio-quinuclyline (S) was prepared analogously to example 1, but based on 104.8 g of triphenylphosphine, 80.8 g of dizopropylazodicarboxylate and 25.7 g of 3-oXi-quinuclidine (R) (Acta Pharm Snec, 1979, 16, 281 ). Thus, 30 g of 3-acetylthioquinuclidine (S) are obtained in the form of a yellow oil (RJ 0.2; the solvent is methylene chloride-methanol 90-10% by volume). Carbon 3 configuration (R) is converted into carbon configuration (S) during the reaction according to the method described in Tet Let, 1981, 22 (33), 3119.
    PRI me R 3. Analogously to example 1, but starting from 6.15 g of 5o-methylene-pristinamycin 1 / and 1 g of 3-mercaptoquinuclidine (R) and after purification by flash chromatography, take 40 cm fractions (solvent - methylene chloride-methanol 85-15 vol. X) and after concentration to dryness of fractions 20-30, 2 g are obtained | 3-quinuclidinyl (R) -5) -thiomethyl-pristinamycin 1 in the form of a beige-colored powder, and so on. 200 C.
    Nuclear Magnetic Resonance Spectrum: 0.58 (dd, I 15 and 5.5, 1H,
    With Zrr; 1.5-2.2 (t,); 2.30
    N
    (t, 1H, 5); 2.35 (d, I 15, 1H, 5ft,); 2.50 (dd, 1H,); 2.60 (dd.
    1H, 56 ,,); 2.78 (m, 1H, -S,
     J v
    2.90-3.10 (m, 1H, -CHg-S- and -SI
    3.15 (m, 1H, -S-CfrT-i); 3.48 (m, 1K
    -S,); 4.95 (dd, 1H, 5e,); 5.28

    (m, 2H, 5o and 4W); 7.87 (m, 1Hx Ig of the 1st isomer); 7.93
    0.85, 1 H,
    (m, 1NkO, 15 1 Hg of the 2-nd isomer).
    eight
    five
    0
    five
    0
    five
    0
    five
    0
    five
    3-Hinuclidinyl (R) -5-thiomethyl - pristinamycin 1d is recrystallized as follows.
    14.15 g are dissolved | 3-quinuclidinyl (R) -5J-thiomethyl 1-pristaminacyna 1d in 75 cm of methanol. 4 cm of distilled water is added to this solution, then left to crystallize at 4 ° C. The resulting crystals are filtered, then rinsed 4 times with 10 cm of a mixture of methanol and water (95-5%). After drying under reduced pressure (90 Pa) at 42 ° C, 10.22 g of white crystals with a mp. 190 s.
    3-Merkypto-quinuclidine (R) was prepared as described in Example 2, but based on 32.5 g of 3-acetylthio-quinuclidine (R) and 35 cm of an aqueous solution of 10N sodium hydroxide. 11.5 g of 3-mercapto-quinuclidine (R) are obtained in the form of white crystals with m.p. and distilled off at 90 ° С and at 930 Pa (oijj-t-12l C, С 1.1, methanol).
    3-Acetylthio-quinuclidine (R) was prepared analogously to example 1, but based on 104.7 g of triphenylphosphine, 30.8 g of diisopropylazodicarboxylate and 25.7 g of 3-hydroxyinuclide (S) (Acta Pharm Snec, 1979, 16, 281). Thus, 33.8 g of 3-acetylthioquinuclidine (R) are obtained in the form of a light brown oil (Rf 0.4; solvent is methylene chloride-methanol 80–20% by volume).
    EXAMPLE 4 Analogously to Example 1, but starting from 3.5 g 5 of methylene pristinamine 1. and 0.6 g of mercaptoquinuclidine (Helv Chim Acta 1974, 57, 2339) and after concentration to dryness, a solid a substance that is stirred in ethyl ether. After filtration, 3.6 g of a beige solid is obtained, which is purified by flash chromatography, to select fractions of 50 cm each (solvent — methylene chloride-methanol 85–15% by volume). After concentrating the fractions 19-35 to dryness, washing with ethyl ether, filtering and then drying the resulting solid under reduced pressure (2.7 kPa) at 20 ° C., 1.2 g of (4-quinuclidinyl) -5th-thiomethyl-acrythinamine 1d are obtained in ground form
    it has a white powder with m.p. 200 C. Nuclear magnetic resonance spectrum (2 isomers at carbon level 5 i in quantities of 85-15 approximately): 0.62 (dd, I 15 and 5.5, 1H,
     5 |,); 1.87 (t, 6H,
    2.20 (t, 1H, 5 (); 2.28 (t, 1H, -CHi-S-); 2.35 (d, I 15, 1H, 5R,); i:, A7 (dd, 1H , 55); 3.10 (t, 6H,
    / CHi,
    -s4-CHi -); 3.22 (dd, 1H,
    17-, r
    -CH /
    -S-); 5.01 (dd, 1H, 5e,); 5.29 (broad, I 5.5, 5ct); 7.86 (m, 0.85 H, l Hg are relative to most isomers); 7.92 (t, 0.15H 1 Hg is a minority isomer).
    Example 5. Analogously to example 1, but starting from 1.2 g of H-methylene virginiamycin S in 20 cm of methanol and 0.21 g of 3-mercapto-quinuclidine (R) / After purification by instant chromatography, take a fraction of 10 cm (solvent - methylene chloride-methanol 95–5% by volume to fraction 35, then methylene chloride-methanol 80–20 obl to dryness concentration of fractions 47–55 and drying under reduced pressure (2.7 kPa) to obtain 0.6 g of 3-quinuclidinyl ( R) l-5d-thiomethylvirginiamycin (S) in the form of a crushed white powder with mp.
    Nuclear Magnetic Resonance Spectrum (2 isomers at 5 carbon level in amounts of about 80-20): 0.4 (dd, I 15 and 5.5, 1K, 5/3)
    1.5-2.2 (m, 5H, .g
    one,
    .3
    N
    5 (j);
    2 (m, 1H, -S-g)); 2.34
    N
    1H, 5ft,); 2.52 (dd, 1H - 2.63 (dd, 1H, 56); 2.78 S.-
    ); 2.85-3.15 (m,
     - ",} - 3, 48 (m, 1H
    4.94 (dd, 1H, 58,);. 5.27 (d wide 1 5, 1H, 5cO; 7.82 (dd, 1 4 and 1, 1 rig of the 1st isomer); 7.9 (dd , I 3 and 1, I Hg of the 2nd isomer).
    Example 6. Analogously to Example 1, but starting from 1.1 g of 5-methylene-virginiamycin (S) in 20 cm of methanol and O, 19 g of 3-mercapto-quinuclidine (S). After purification with an instant chromatogram, picia, selection of 10 cm fractions
    (solvent - methylene chloride - methanol 90-10 vol.%), concentration of dB of dry fractions 19-32 and drying under low pressure (2.7 kPa) at ZO C give 0.5 g of 3-quinuclidinyl (S) - 50-thiomethyl-virginiamycin (S) in the form of a pale yellow powder with so pl.
    190 C.
     ),
    ten
    Nuclear Magnetic Resonance Spectrum (2 isomers at a carbon level of 5 ° in amounts of about 85–15% by volume): 0.39 (dd, I 15 and 5. 1H, 1.5-2.3 (t, 5H,

    Int
    2.34 (d, I 15, 1H, 5); 2.52 (dd, 1H,); 2.64 (dd, 1H, 562); 20 2.66 (dd, 1H, S-r-V); 2.90-3.2
     N "h

    (t, 6H, 1H, -CH -S-, and
    SNx -ni
    N 25
    but-
    3.3-3.5 (t, 1H,); 4.95 (dd,
    1H: 6i); 5.27 (d wide, 1H, 5pt-); 7.80 (dd, 1 4 and 1 1HifO, 85, | isomer); 7.90 (dd, I 4 and 1, 1XX X0.15, 1 Nb of the 2nd isomer).
    Example 7. Analogously to Example 2, but starting from 1.62 g of 3-mercaptoquinuclidine (S) and mixing
    ., at -20 s for 20 h, is obtained after concentration to dryness under reduced pressure (2.7 kPa) at a DL with 11.4 g of a beige-colored substance, which is stirred in 100 cm of simple
    Q diethyl ether, filtered, then rinsed 3 times with 20 cm of the same solvent. This product can be recrystallized from acetone, as described in Example 2, to obtain 6.6 g of 3-quinuclidinyl (5) -5o-thio-methyl-pristinagticin 1c in the form of white crystals with m.p. 198-200 s, whose characteristics are identical to the characteristics of the product obtained
    50 in example 2 and containing 3% relative to a smaller amount of isomer, high-resolution liquid chromatography (HPLC).
    Example8. In a solution of 1 g
    55 50-methyl propylene iicin 1d in
    20 cm of acetone are added at -20 ° C over 1 hour to 0.16 g of 3-mercapto-quinuclidine (S) in solution in 5 cm of acetone. After 18 hours of stirring with filter 16
    rut the reaction mixture1, wash the solid 3 times with 2 cm of acetone. After air drying, 0.6 g of 3-quinuclidinyl (S) 3-5a-thiomethyl-pristinamycin 1d is obtained in the form of white crystals with m.p. 190 C, the characteristics of which are identical to those of the product obtained in Example 2 and containing 3% of the minority isomer, as determined by HPLC.
    Sample To a solution of 1.2 g of 54-methylene-pristinamycin 1d in 15 cm of acetone is added at -78 with 0.16 g of 3-mercapto-quinuclidine (S) in a solution of 5 cm of acetone, then the resulting solution is stirred under nitrogen for 2A h at -78 s. The reaction mixture is then concentrated to dryness under reduced pressure (2.7 Pa) at 30 ° C to obtain 1.4 g of a creamy white solid containing 5% of the lesser amount of isomer determined by HPLC and having characteristics identical to those of the product obtained in example 2.
    Example 10. The study of the biological activity of the compounds obtained.
    Testing the obtained compounds for in vitro bacteriostatic activity. To a series of plates containing 20 cm of culture medium (Hinton agar), 1/10 of this volume of a series of geometrically increasing dilutions (geometric progression ratio 2) of the test compound is added. The plates were seeded with a multipoint inoculum, which produces a spot of 104 units of the microorganism forming a colony in tryptoseum soy broth, incubated for 18 hours at 37 ° C and diluted 1/100 in the same medium.
    After seeding the microorganisms, the plates are incubated for 24 hours at 37 ° C. .
    The minimum inhibitory concentration (M.I.K) is the lowest concentration at which the development of the microorganism is inhibited.
    The test results are presented in Table. one.
    Test compounds obtained for activity against intraperitoneal
    3201
    infections in mice. The mouse was in one intraperitoneal injection of 0.5 cm of a stirred-up culture of the age of 18 hours of the test — a microorganism in the Brain and Cardiac Injection (Difco) diluted with 5% swine MUSCH1NOM. Such an injection causes the death of control animals within 24-48 hours. The test compound Q is administered subcutaneously.
    twice at 5-hour intervals on the day of injection, with the first dose administered 1 hour after the injection of the microorganism. Single doses were used in a volume of 15 I 50 cm kg.
     - is the dose of the test compound administered with each subcutaneous injection, resulting in 50% of the test animals surviving during the test period (8 days).
    Test microcycle CIO in vitro. This study is designed to assess the potential activity of products 25 by initiating the appearance of microderms in Chinese Ovarian Ovary Cells (CHO) with and without metabolic activation.
    Cyclophosphamide (the case of the activation of 30 methyl methanesulfonate (the case without activation) was used in parallel as a positive control.
    Chinese hamster fibroblast cell cultures (CHO-K1) are exposed to the test compound in the presence or absence of exogenous metabolic activation. After exposure to the test compounds, the cells were fixed and stained. Q The slides were then analyzed to detect the micro dermis.
    Cells were examined 44 h after the end of exposure.
    In these studies, the complete medium was prepared based on the culture medium, Hamis F-12 manufactured by Flow Laboratories.
    50 wt.% Were added to the Hamis F-12 medium: serum of calf embryo lOj penicillin (5000 mecch spleen units per 1 ml) and streptomycin (5000 mcc / ml in solution) 1; glutamine 1L.
    The metabolic activation system (S9 mix) used in the test35
    55
    xy, is a homogeneous preparation of the liver volume (S9) of rats previously treated with polychlorinated biphenyl containing 54%
    Cl Aroclor 123L, to which you can get KoTiaKTopbi and mineral salts.
    Mixture S9 is prepared in the following manner.
    A solution of nicotinamide cofactors denindinucleotide phosphate, NP; NADP (0.1 mol) 0.30; ultrapure water 3.40; isoshelt (0.15 MAP) 8.7.
    A solution of S 9: 1 ml prepared as follows.
    Male rats (Spreig-Dawley breed) are subjected to intraperitoneal injection of Aroclor 125A (500 mg, kg) in a volume of 25 MP / kg and killed after 5 days. A field of this is aseptically removed the liver and homogenized in the presence of KCl (0.15 mol) at TeMnepaTiT e below. The homogeneous preparation is centrifuged for 10 minutes at a speed of 9000g, the upper layer (S9) is bottled and stored in liquid nitrogen at -ISO
    For a concentration of 2 cups of Nunc (10 cm in area), approximately 150,000 cells contained in 2 MP of complete medium are seeded and incubated at 37 ° C for 4 hours.
    At the end of the incubation period, the medium with the substance is poured, the plates are rinsed with PBS and incubated with 2 MP of complete medium.
    44 h after the end of the treatment, the cells are stained with 1 ml of MEY Grunwald solution for 3 minutes. Then 1 ml of distilled water is added over 1 minute. The cells are rinsed with 1 ml of distilled water.
    Giensa diluted 1/3 with distilled water is added over 20 minutes. Then the cells are rinsed. The bottom of the cup is removed and glued onto a glass with a drop of Eukitt glue.
    One of the two slides obtained from the two cups was analyzed for counting. Count the number of cells with micro drami per 1000 of all cells.
    The test results are presented in table 2 and 3.
    LD, jg of the compounds obtained are higher than 150 mg / kg when tested in mice after subcutaneous administration.
    The compounds obtained by the proposed method also exhibit a synergy when they are combined with pristinamycin 11 or with a soluble derivative

    6165
    ten
    20
    25
    . O14
    Tinamycin 11 „(French patent N 2549260).
    Thus, the compounds of general formula (I) can be used in free form or in the form of an addition salt with a pharmaceutically acceptable acid, in pure form or in combination with pristinamycin Id or preferably with a soluble derivative of pristinamycin Ilg in pharmaceutical compositions. In addition, these compositions may contain any other pharmaceutically compatible substance that may be inert or physiologically active.
    In human therapy, the compounds obtained are particularly useful in the treatment of infections of bacterial origin. Doses depend on the desired effect and on the time of treatment. For adults, they are usually between 2000 and 4000 mg per day for parenteral administration, especially for intravenous administration with slow perfusion.
    权利要求:
    Claims (1)
    [1]
    Formula invented
    the shadows
    thirty
    The method of obtaining derivatives of pristinamycin of the general formula
    R
    CH
    35
    . 0 N-vCH2SR
    KV-io
    ABOUT
    40
    five
    0
    five
    1 fHj.
    -NH -L. b
    u
    where Y is hydrogen or dimethylamino;
    R is 3- or 4-quinuclidinip, as a single isomer or mixture of isomers or their acid addition salts, characterized in that the pristinamycin derivative of the general formula
    G 3
    . PA
    about
    15
    where Y has the indicated meanings, is reacted with a thiol of the general formula
    R - SH,
    where R has the indicated meanings, in the medium of an organic solvent, followed by drying of the target compound either as a base or as an acid addition salt.
    161652016
    Priority n and m:
    05.22.86 when Y is in the methylamino group, R is Nil.
    05/21/87 when the Y is in the dimethylamino group, R
    d DINIL.
    on para and 3 of 22 .05.86 when Y is hydrogen or a methylamino group, R is 3-quinuclidinyl.
    05.21.87 when Y is hydrogen, or dimethylamino group, R is 4-hinukpiDINIL.
    Known compounds:
    a) (4-methyl-1-piperazinyl) propyl thio-methylpristine-Ijj
    b) 55- (1-methyl-4-PIP yrididi) about methylpristin-amycin 1d
    b) 58- (2-diethylaminoethyl) thiomethylpriscinamycin 1d
    Table 1
    20
    .five
    20
    34
    Non-clastic product
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0116208B1|1988-03-30|Mitomycin analogues
    US4595693A|1986-06-17|Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
    CS273153B2|1991-03-12|Method of new 2,4-diamino-5-substituted pyrimidine derivatives production
    SU1616520A3|1990-12-23|Method of producing derivatives of pristinamicine
    US4268676A|1981-05-19|Mitomycin analogs
    AT394725B|1992-06-10|Process for the preparation of novel mitomycin-C analogues
    SU1586521A3|1990-08-15|Method of producing derivatives of glycopeptides
    SU980627A3|1982-12-07|Process for producing n-desmethylvinblastine, vincristine, n-desmethylleurosine, h-dimethyl-n-formylleurosine, n-dismethyl-n-|-vinblastine, n-desmethyl-n-|-leurosine or their salts
    WO2000012484A1|2000-03-09|Tan-1057 derivatives
    DK145823B|1983-03-14|ANALOGY PROCEDURE FOR PREPARING AMIDES OF PSEUDOMONIC ACID
    MX2007013683A|2007-12-03|Antitumoral tetrahydro-pyrimidines.
    CS198195B2|1980-05-30|Process for preparing 4-imino-1,3-diazabicyclo/3,1,0/hexan-2-one
    DE69819340T2|2004-08-19|OPTICALLY PURE CAMPTOTHECIN ANALOG, OPTICALLY PURE SYNTHESIS INTERMEDIATE AND METHOD FOR THE PRODUCTION THEREOF
    EP0290003A2|1988-11-09|Imidazoles
    CN107746423B|2020-02-14|Ergosta-7, 22-diene-3-ketoxime, preparation method thereof and application thereof in preparation of antibacterial drugs
    AU2006274690A1|2007-02-08|Antitumoral compounds
    EP0003286B1|1982-03-24|Derivatives of ergopeptide alkaloids, process for their preparation and pharmaceutical compositions containing them
    JP4616981B2|2011-01-19|New active substances, their production and use
    SU1258327A3|1986-09-15|Method of producing 7-substituted compounds of 9a-methoxy-mitosane
    DE2042253A1|1971-03-04|Process for the preparation of new heterocyclic compounds
    DE2424540A1|1974-12-12|ERGOLINCARBAMATE
    US5374739A|1994-12-20|Mitomycin analogs
    US9758503B1|2017-09-12|Coumarin-gossypol derivatives with antitumor activities and a method of preparing the same
    WO1983002775A1|1983-08-18|Ergot alkaloids, manufacturing process thereof and pharmaceutical preparations containing them
    US6350743B1|2002-02-26|Cytotoxic pyridoacridine alkaloids
    同族专利:
    公开号 | 公开日
    NZ220380A|1989-02-24|
    FR2599036B1|1988-09-09|
    GR3002558T3|1993-01-25|
    NL300010I1|2000-08-01|
    JP2659531B2|1997-09-30|
    EP0248703B1|1991-05-15|
    EP0248703A1|1987-12-09|
    DK258587A|1987-11-23|
    KR880013934A|1988-12-22|
    ZA873639B|1987-11-17|
    IE60656B1|1994-08-10|
    CA1271297A|1990-07-03|
    FI84355C|1991-11-25|
    AT63563T|1991-06-15|
    IL82564A|1991-04-15|
    MX9203577A|1992-09-01|
    DE10075012I1|2000-08-31|
    JPH08319236A|1996-12-03|
    FR2599036A1|1987-11-27|
    PT84934B|1990-02-08|
    DE10075012I2|2006-02-02|
    BR1101133A|1999-12-07|
    DK172949B1|1999-10-11|
    KR950001020B1|1995-02-07|
    AU601426B2|1990-09-13|
    JP2558282B2|1996-11-27|
    FI872236A|1987-11-23|
    AU7323987A|1987-11-26|
    JPS6322095A|1988-01-29|
    LV5268A3|1993-10-10|
    LU90732I2|2001-04-17|
    DE3770048D1|1991-06-20|
    FI872236A0|1987-05-21|
    IL82564D0|1987-11-30|
    ES2032457T3|1993-02-16|
    PT84934A|1987-06-01|
    DK258587D0|1987-05-21|
    IE871317L|1987-11-22|
    NL300010I2|2001-01-02|
    US4798827A|1989-01-17|
    FI84355B|1991-08-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2549065B1|1983-07-13|1985-10-25|Rhone Poulenc Sante|NOVEL SYNERGISTIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    FR2549062B1|1983-07-13|1985-10-25|Rhone Poulenc Sante|NOVEL SYNERGISTIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    FR2549063B1|1983-07-13|1985-10-25|Rhone Poulenc Sante|NOVEL SYNERGISTIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    FR2549064B1|1983-07-13|1985-10-25|Rhone Poulenc Sante|NOVEL SYNERGISTIN DERIVATIVES USEFUL FOR THE PREPARATION OF NEW ANTIMICROBIAL DRUGS AND THEIR PREPARATION|
    FR2576022B1|1985-01-11|1987-09-11|Rhone Poulenc Sante|NOVEL DERIVATIVES OF PRISTINAMYCIN II B, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|FR2664894B1|1990-07-19|1994-08-19|Rhone Poulenc Sante|
    FR2689518B1|1992-04-01|1995-04-07|Rhone Poulenc Rorer Sa|Microorganisms, preparation process and use.|
    US5242938A|1992-08-27|1993-09-07|Merck & Co., Inc.|Derivatives of virginiamycin M1|
    IL121821A|1993-02-17|2000-02-17|Rhone Poulenc Rorer Sa|Process for purifying a group A minority component of streptogramin some such purified components and their uses|
    FR2723373B1|1994-08-02|1996-09-13|Rhone Poulenc Rorer Sa|PURIFIED FORM OF STREPTOGRAMINS, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|
    FR2755857B1|1996-11-19|1998-12-24|Rhone Poulenc Rorer Sa|STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON QUINUPRISTINE AND DALFOPRISTINE AND THEIR PREPARATION|
    FR2766489B1|1997-07-28|1999-08-27|Rhone Poulenc Rorer Sa|STREPTOGRAMIN DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM|
    US6187746B1|1997-12-16|2001-02-13|Rhone-Poulenc Rorer S.A.|Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof|
    FR2796949B1|1999-07-27|2001-09-21|Aventis Pharma Sa|STREPTOGRAMIN DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8607270A|FR2599036B1|1986-05-22|1986-05-22|NOVEL SYNERGISTIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME|LV930070A| LV5268A3|1986-05-22|1993-01-26|promotes the acquisition of derivatives|
    [返回顶部]